How would you approach a patient with BRAF V600E mutated dMMR stage II colon cancer?

Topics: Gastrointestinal Cancers • Medical Oncology • Colorectal Cancer

Would you consider adjuvant chemotherapy?

Answer from: Medical Oncologist at Academic Institution

Assuming this was an adequately staged cancer (at least 12 lymph nodes examined), BRAF should not play a role in the decision making for adjuvant therapy. This patient is MSI-high (MMR deficient) and patients with MSI high tumors have a better prognosis than MSS patients (Popat et al., PMID 15659508...

Comments

Medical Oncologist at Pacific Cancer Care
Would you give adjuvant therapy if the patient had...

Medical Oncologist at Aurora Advanced Healthcare
Thanks for your recommendations, really helpful. I...

Medical Oncologist at Cedars-Sinai Medical Center
No chemo. There are 3 strikes against giving adjuv...

Medical Oncologist at Clinical Instructor
The question of additional high risk factors on dM...

Medical Oncologist

One could consider checking circulating tumor DNA. This is an evolving technology in colon cancer that might sway you to offering adjuvant chemotherapy if this test suggested a high risk of recurrence.

Comments

Medical Oncologist at Florida Cancer Specialists and Research Institute
Which assay do you use?

Medical Oncologist
Two very helpful articles are: JAMA Oncology 9 Ma...

Related Questions